NewEdge Wealth LLC Has $889,000 Stock Holdings in Icon Plc $ICLR

NewEdge Wealth LLC increased its holdings in shares of Icon Plc (NASDAQ:ICLR) by 81.9% in the first quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 8,038 shares of the medical research company’s stock after purchasing an additional 3,619 shares during the quarter. NewEdge Wealth LLC’s holdings in Icon were worth $889,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently bought and sold shares of ICLR. Allspring Global Investments Holdings LLC raised its holdings in shares of Icon by 1.1% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 1,080,192 shares of the medical research company’s stock worth $203,800,000 after acquiring an additional 11,335 shares during the period. Jennison Associates LLC acquired a new position in Icon in the 4th quarter worth $123,542,000. Trinity Street Asset Management LLP increased its holdings in Icon by 23.1% during the 4th quarter. Trinity Street Asset Management LLP now owns 1,072,428 shares of the medical research company’s stock worth $195,418,000 after purchasing an additional 201,455 shares in the last quarter. Calamos Advisors LLC bought a new position in Icon during the 4th quarter worth about $4,829,000. Finally, OVERSEA CHINESE BANKING Corp Ltd acquired a new stake in shares of Icon in the 4th quarter valued at about $2,960,000. 95.61% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

ICLR has been the subject of several recent research reports. Piper Sandler cut Icon to a “neutral” rating in a research report on Thursday, May 28th. Truist Financial raised Icon from a “hold” rating to a “buy” rating and lifted their target price for the company from $159.00 to $207.00 in a research report on Tuesday, June 30th. Weiss Ratings cut Icon from a “sell (d+)” rating to a “sell (d)” rating in a research note on Friday, May 29th. Robert W. Baird upped their price target on Icon from $168.00 to $186.00 and gave the stock an “outperform” rating in a research report on Thursday, June 25th. Finally, Bank of America raised their price target on shares of Icon from $125.00 to $150.00 and gave the stock an “underperform” rating in a research note on Thursday, June 25th. Seven research analysts have rated the stock with a Buy rating, six have issued a Hold rating and three have given a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $168.73.

Icon Price Performance

Shares of NASDAQ ICLR opened at $168.78 on Tuesday. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.14 and a quick ratio of 1.14. The business has a 50-day moving average of $152.21 and a 200-day moving average of $135.77. The stock has a market capitalization of $12.92 billion, a price-to-earnings ratio of 30.03, a PEG ratio of 8.14 and a beta of 1.22. Icon Plc has a fifty-two week low of $66.57 and a fifty-two week high of $203.91.

About Icon

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.